Autonomix Medical (NASDAQ:AMIX) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Autonomix Medical (NASDAQ:AMIX) to a hold rating in a report published on Tuesday morning,Zacks.com reports.

A number of other research firms have also recently weighed in on AMIX. Maxim Group lowered their price target on Autonomix Medical from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, May 18th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $2.00.

Autonomix Medical Price Performance

AMIX opened at $0.39 on Tuesday. The stock has a market cap of $2.71 million, a P/E ratio of -0.11 and a beta of -1.43. The stock’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $0.50. Autonomix Medical has a 1-year low of $0.20 and a 1-year high of $2.64.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.